برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Korsuva (difelikefalin) Injection Date of Approval: August 23, 2021 Company: Cara Therapeutics, Inc. Treatment for: Chronic Kidney Disease-Associated Pruritus Korsuva (difelikefalin) is a selective peripheral kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). https://t.me/ppdprogram

➡️Twyneo (tretinoin and benzoyl peroxide) Cream Date of Approval: July 26, 2021 Company: Sol-Gel Technologies, Ltd. Treatment for: Acne Twyneo (tretinoin and benzoyl peroxide) is a topical retinoid and antibacterial fixed-dose combination for the treatment of acne vulgaris in adults and children 9 years of age and older. https://t.me/ppdprogram

➡️Bylvay (odevixibat) Capsules Date of Approval: July 20, 2021 Company: Albireo Pharma, Inc. Treatment for: Progressive Familial Intrahepatic Cholestasis (PFIC) Bylvay (odevixibat) is an ileal bile acid transport (IBAT) inhibitor for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). https://t.me/ppdprogram

➡️(fexinidazole) Tablets Date of Approval: July 16, 2021 Company: Drugs for Neglected Diseases Initiative Treatment for: Trypanosomiasis Fexinidazole is a nitroimidazole antibacterial indicated for the treatment of human African trypanosomiasis (African sleeping sickness) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. https://t.me/ppdprogram

➡️Kerendia (finerenone) Tablets Date of Approval: July 9, 2021 Company: Bayer Treatment for: Chronic Kidney Disease Associated with Type 2 Diabetes Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA) for the treatment of patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). https://t.me/ppdprogram

➡️Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Injection Date of Approval: June 30, 2021 Company: Jazz Pharmaceuticals plc Treatment for: Acute Lymphoblastic Leukemia Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). https://t.me/ppdprogram

➡️Verkazia (cyclosporine) Ophthalmic Emulsion Date of Approval: June 23, 2021 Company: Santen Inc. Treatment for: Vernal Keratoconjunctivitis Verkazia (cyclosporine) is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. https://t.me/ppdprogram

➡️Soaanz (torsemide) Tablets Date of Approval: June 14, 2021 Company: Sarfez Pharmaceuticals Treatment for: Edema Soaanz (torsemide) is a loop diuretic indicated for the treatment of edema associated with heart failure or renal disease in adults. https://t.me/ppdprogram

➡️Wegovy (semaglutide) Injection Date of Approval: June 4, 2021 Company: Novo Nordisk Treatment for: Obesity Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are overweight (BMI ≥27 kg/m2) or obese (BMI ≥30 kg/m2). https://t.me/ppdprogram

➡️Astepro Allergy (azelastine) Nasal Spray Date of Approval: June 17, 2021 Company: Bayer HealthCare LLC Treatment for: Allergic Rhinitis Astepro Allergy (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis. https://t.me/ppdprogram

➡️Lybalvi (olanzapine and samidorphan) Tablets Date of Approval: May 28, 2021 Company: Alkermes plc Treatment for: Schizophrenia, Bipolar Disorder Lybalvi (olanzapine and samidorphan) is a combination of an established antipsychotic agent (olanzapine) and a novel μ-opioid receptor antagonist (samidorphan) for the treatment of schizophrenia and bipolar I disorder. https://t.me/ppdprogram

➡️Zegalogue (dasiglucagon) Injection Date of Approval: March 22, 2021 Company: Zealand Pharma A/S Treatment for: Hypoglycemia Zegalogue (dasiglucagon) is a glucagon analog antihypoglycemic agent for the treatment of severe hypoglycemia in diabetes patients aged 6 years and older. https://t.me/ppdprogram

➡️Nasonex 24HR Allergy (mometasone furoate monohydrate) Nasal Spray Date of Approval: March 17, 2022 Company: Perrigo Company plc Treatment for: Allergic Rhinitis Nasonex 24HR Allergy (mometasone furoate monohydrate) is a corticosteroid nasal spray available over-the-counter for the temporary relief of the symptoms of hayfever or other upper respiratory allergies. https://t.me/ppdprogram

➡️Hyftor (sirolimus) Topical Gel Date of Approval: March 22, 2022 Company: Nobelpharma America, LLC Treatment for: Facial Angiofibroma Associated with Tuberous Sclerosis Hyftor (sirolimus topical gel) is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older. https://t.me/ppdprogram

➡️Pluvicto (lutetium lu 177 vipivotide tetraxetan) Injection Date of Approval: March 23, 2022 Company: Novartis Treatment for: Prostate Cancer Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent indicated for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). https://t.me/ppdprogram

➡️Opdualag (nivolumab and relatlimab-rmbw) Injection Date of Approval: March 18, 2022 Company: Bristol Myers Squibb Treatment for: Melanoma Opdualag (nivolumab and relatlimab-rmbw) is programmed death receptor-1 (PD-1) blocking antibody and lymphocyte activation gene-3 (LAG-3) blocking antibody combination indicated for the treatment of unresectable or metastatic melanoma. https://t.me/ppdprogram

➡️Ztalmy (ganaxolone) Oral Suspension Date of Approval: March 18, 2022 Company: Marinus Pharmaceuticals, Inc. Treatment for: CDKL5 Deficiency Disorder Ztalmy (ganaxolone) is neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) https://t.me/ppdprogram

➡️Spikevax (Moderna COVID-19 Vaccine) (COVID-19 Vaccine, mRNA) Injection - formerly mRNA-1273 Date of Approval: January 31, 2022 Company: Moderna, Inc. Treatment for: Prevention of COVID-19 Spikevax (COVID-19 Vaccine, mRNA) is an mRNA vaccine indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. https://t.me/ppdprogram

➡️Vonjo (pacritinib) Capsules Date of Approval: February 28, 2022 Company: CTI BioPharma Corp. Treatment for: Myelofibrosis Vonjo (pacritinib) is a JAK2/FLT3 multikinase inhibitor for the treatment of myelofibrosis patients with severe thrombocytopenia. https://t.me/ppdprogram

➡️Pyrukynd (mitapivat) Tablets Date of Approval: February 17, 2022 Company: Agios Pharmaceuticals, Inc. Treatment for: Pyruvate Kinase Deficiency Pyrukynd (mitapivat) is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. https://t.me/ppdprogram